1-4 of 4
Claudia Walasek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas C.P. Cross, PhD, Andrzej Hellman, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Medina Almeida, Arpad Illes, MD PhD, Cristalina Fernandez, Luca Dezzani, Angela Pellegrino, Chiara Costantini, Claudia Walasek, Giuseppe Saglio, Juan Luis Steegmann, MD, Michele Baccarani
Journal: Blood
Blood (2015) 126 (23): 4040.
https://doi.org/10.1182/blood.V126.23.4040.4040
Published: 2015
Journal Articles

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Francis J Giles, MB, MD, FRCPI, FRCPath, Michele Baccarani, MD, Tim H. Brümmendorf, MD, Andrzej Hellmann, MD, Francois-Xavier Mahon, MD, PhD, Gianantonio Rosti, Giuseppe Saglio, MD, Juan Luis Steegmann, MD, PhD, Gert J. Ossenkoppele, MD PhD, Maria Asunción Echeveste, Norbert Gattermann, MD, Laimonas Griskevicius, Philipp D. le Coutre, MD, Bruno Martino, Tamas Masszi, MD, PhD, Ljubomir Petrov, Delphine Rea, MD, PhD, Johan Richter, MD, PhD, Jesper Stentoft, MD, PhD, Consultant in Hematology, Michel Tulliez, MD, Peter Schuld, PhD, Angela Pellegrino, Claudia Walasek, Nicholas C.P. Cross, PhD, Andreas Hochhaus, MD
Journal: Blood
Blood (2013) 122 (21): 4030.
https://doi.org/10.1182/blood.V122.21.4030.4030
Published: 2013
Journal Articles

Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib

Katrin Wenn, Lena Tomala, Fabian Beier, MD, Stefan Wilop, MD, Lucia Vankann, Christian Hasenbank, Oliver Frank, Claudia Walasek, Andreas Hochhaus, MD, Frank Giles, MD MB, Steffen Koschmieder, Patrick Ziegler, PhD, Tim H. Brümmendorf, MD
Journal: Blood
Blood (2013) 122 (21): 1471.
https://doi.org/10.1182/blood.V122.21.1471.1471
Published: 2013
Journal Articles

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Juan Luis Steegmann, MD, Luis Felipe Casado Montero, MD, PhD, Maria Teresa Gomez-Casares, MD, Maria Rozman, MD, Maria Asunción Echeveste, J Valentin Garcia-Gutierrez, MD, PhD, Jose Luis Sastre, MD, Angel Ramirez Payer, MD, Eduardo Olavarria, MD, Ferran Vall, MD, Blanca Xicoy, MD, PhD, Pilar Giraldo, MD PhD, Eulogio Conde, MD, PhD, Rolando Omar Vallansot, MD, Jose Luis Lopez-Lorenzo, MD, Luis Palomera, MD, Soraya Ruiz, PhD, Laura Casas, Claudia Walasek, Dolors Colomer
Journal: Blood
Blood (2013) 122 (21): 5190.
https://doi.org/10.1182/blood.V122.21.5190.5190
Published: 2013